Lipoprotein(a) Explained: The Silent Cardiovascular Risk Marker Most Doctors Don't Test

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making changes to your medications, supplements, or health regimen.

You've had your cholesterol checked. Your LDL looks fine, your HDL is decent, and your triglycerides are in range. Yet cardiovascular disease remains the leading cause of death worldwide — and for a significant portion of people, a single lab value they've never heard of may be quietly driving their risk. That value is Lipoprotein(a), written as Lp(a) and pronounced "L-P-little-a."

Lp(a) is one of the most clinically important cardiovascular biomarkers that most routine blood panels simply don't include. Understanding what it is, how to test for it, and what to do with your results could be one of the most impactful steps you take for your long-term heart health.

What Is Lipoprotein(a)?

Lipoprotein(a) is a type of LDL-like particle with an additional protein called apolipoprotein(a) — or apo(a) — attached to it via a disulfide bond. This unique structure makes Lp(a) particularly dangerous for several reasons:

• It promotes atherosclerosis (plaque buildup in arteries) more aggressively than standard LDL
• It has pro-thrombotic (clot-promoting) properties due to its structural similarity to plasminogen, a clot-dissolving protein
• It carries oxidized phospholipids that trigger arterial inflammation
• It contributes to aortic valve calcification, a condition that can lead to aortic stenosis

According to research published in the Journal of the American College of Cardiology, elevated Lp(a) is an independent risk factor for myocardial infarction (heart attack), stroke, and peripheral artery disease — regardless of your LDL or total cholesterol levels ([JACC, 2022](https://www.jacc.org/doi/10.1016/j.jacc.2022.01.024)).

Why Lp(a) Is Largely Genetic

Unlike LDL cholesterol, which responds significantly to diet, exercise, and statins, Lp(a) levels are approximately 70–90% determined by genetics — specifically by the LPA gene. This means:

• Lifestyle changes have minimal impact on Lp(a)
• Statins, the most commonly prescribed cholesterol-lowering drugs, do not meaningfully lower Lp(a) and may even slightly raise it
• If you have elevated Lp(a), it's likely a lifelong condition that warrants ongoing monitoring

The National Institutes of Health (NIH) notes that roughly 1 in 5 people worldwide — approximately 1.4 billion individuals — have elevated Lp(a) levels that increase cardiovascular risk ([NIH MedlinePlus](https://medlineplus.gov/genetics/gene/lpa/)).

How Is Lp(a) Measured?

The Test

Lp(a) is measured via a simple blood draw, typically reported in one of two units:

• mg/dL (milligrams per deciliter) — most common in the United States
• nmol/L (nanomoles per liter) — preferred by many cardiologists and used in European guidelines

> Important: These units are NOT interchangeable with a simple conversion factor because Lp(a) particle sizes vary. Always note which unit your lab uses.

Reference Ranges

• Optimal: < 30 mg/dL (< 75 nmol/L) — Low risk
• Borderline: 30–50 mg/dL (75–125 nmol/L) — Moderate risk
• High: > 50 mg/dL (> 125 nmol/L) — High risk
• Very High: > 100 mg/dL (> 250 nmol/L) — Very high risk

The European Atherosclerosis Society (EAS) recommends that all adults be tested at least once for Lp(a), with more frequent monitoring for those with elevated levels or a family history of premature cardiovascular disease ([EAS Consensus Statement, 2022](https://www.atherosclerosis-journal.com/article/S0021-9150(22)00160-5/fulltext)).

Who Should Get Tested?

The American Heart Association and EAS recommend Lp(a) testing for:

• Anyone with a family history of premature heart disease (before age 55 in men, 65 in women)
• Patients with premature atherosclerotic cardiovascular disease (ASCVD) despite normal LDL
• People with familial hypercholesterolemia (FH)
• Individuals with recurrent cardiovascular events despite optimal statin therapy
• Anyone with aortic valve stenosis without other clear risk factors
• First-degree relatives of someone with confirmed high Lp(a)

If you've had a heart attack or stroke and your traditional risk factors don't fully explain it, Lp(a) testing is especially warranted.

What Raises and Lowers Lp(a)?

Factors That May Raise Lp(a)

• Kidney disease (nephrotic syndrome, chronic kidney disease)
• Hypothyroidism (untreated)
• Menopause (estrogen decline can raise Lp(a))
• Inflammatory conditions
• High dietary intake of trans fats

Factors That May Lower Lp(a)

• Niacin (nicotinic acid): Can reduce Lp(a) by 20–30%, though clinical outcome benefits remain debated ([NIH PubMed](https://pubmed.ncbi.nlm.nih.gov/20031882/))
• PCSK9 inhibitors (evolocumab, alirocumab): Reduce Lp(a) by approximately 20–30% as a secondary effect
• Aspirin: May modestly reduce Lp(a)-associated thrombotic risk in high-risk individuals
• Hormone replacement therapy (HRT): Oral estrogen can lower Lp(a) in postmenopausal women
• Emerging RNA-based therapies: Pelacarsen (an antisense oligonucleotide) and olpasiran (a small interfering RNA) are in Phase 3 trials and can reduce Lp(a) by 70–90% ([FDA Pipeline, 2024](https://www.fda.gov/patients/drug-development-process/step-3-clinical-research))

What Doesn't Work

• Statins (may slightly increase Lp(a))
• Diet and exercise (minimal effect)
• Most standard lipid-lowering supplements

Managing Elevated Lp(a): A Comprehensive Strategy

Since Lp(a) itself is difficult to lower with current therapies, management focuses on aggressively controlling all other modifiable cardiovascular risk factors:

1. Optimize Your LDL

Since Lp(a) adds to LDL-driven risk, driving your LDL as low as possible becomes even more important. Guidelines suggest LDL < 70 mg/dL for high-risk individuals, and < 55 mg/dL for very high-risk patients.

2. Control Blood Pressure

Hypertension compounds Lp(a)-driven arterial damage. Target < 130/80 mmHg.

3. Eliminate Smoking

Smoking dramatically amplifies the pro-inflammatory and pro-thrombotic effects of elevated Lp(a).

4. Manage Inflammation

Monitor high-sensitivity CRP (hsCRP). Chronic inflammation accelerates Lp(a)-driven plaque progression.

5. Consider Aspirin Therapy

For high-risk individuals with elevated Lp(a), low-dose aspirin may be appropriate — discuss with your cardiologist.

6. Watch for Aortic Valve Disease

Regular echocardiograms may be warranted for those with very high Lp(a) to monitor for early aortic valve calcification.

The Future of Lp(a) Treatment

Two RNA-based drugs are in late-stage trials: Pelacarsen (Novartis), an antisense oligonucleotide, and Olpasiran (Amgen), a siRNA therapy that reduces Lp(a) by up to 90%. If Phase 3 trials confirm cardiovascular outcome benefits, these could become the first FDA-approved Lp(a)-lowering therapies — a potential game-changer for the estimated 64 million Americans with elevated Lp(a).

Key Takeaways

• Lp(a) is a genetically determined cardiovascular risk factor independent of LDL cholesterol
• Elevated Lp(a) (> 50 mg/dL or > 125 nmol/L) significantly increases risk of heart attack, stroke, and aortic valve disease
• Standard cholesterol panels do NOT include Lp(a) — you must request it specifically
• Current management focuses on aggressively reducing all other cardiovascular risk factors
• Promising RNA-based therapies are in late-stage clinical trials
• Everyone should be tested at least once; those with family history or premature ASCVD should be prioritized

Knowing your Lp(a) number is one of the most powerful steps you can take toward understanding your true cardiovascular risk — and it starts with a single blood test.

---

Take Control of Your Health Data

Ready to cross-reference your medications, supplements, and lab results in one place? [Health Intelligence Analyzer](/) helps you identify potential interactions, flag abnormal lab values, and optimize your health regimen with AI-powered insights. Start your free analysis today.